Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia | Zendy

Sébastien Maury | Zendy; Sylvie Chevret | Zendy; Xavier Thomas | Zendy; Dominik Heim | Zendy; Thibaut Leguay | Zendy; Françoise Huguet | Zendy; Patrice Chevallier | Zendy; Mathilde Hunault | Zendy; Nicolas Boissel | Zendy; Martine EscoffreBarbe | Zendy; U Hess | Zendy; Norbert Vey | Zendy; JeanMichel Pig | Zendy; Thorsten Braun | Zendy; Jean-Pierre Marolleau | Zendy; JeanYves Cahn | Zendy; Yves Chalandon | Zendy; Véronique Lhéritier | Zendy; Kheïra Beldjord | Zendy; Marie C. Béné | Zendy; Norbert Ifrah | Zendy; Hervé Dombret | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

Author(s) -

Sébastien Maury,

Sylvie Chevret,

Xavier Thomas,

Dominik Heim,

Thibaut Leguay,

Françoise Huguet,

Patrice Chevallier,

Mathilde Hunault,

Nicolas Boissel,

Martine EscoffreBarbe,

U Hess,

Norbert Vey,

JeanMichel Pig,

Thorsten Braun,

Jean-Pierre Marolleau,

JeanYves Cahn,

Yves Chalandon,

Véronique Lhéritier,

Kheïra Beldjord,

Marie C. Béné,

Norbert Ifrah,

Hervé Dombret

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1605085

Subject(s) - rituximab , lineage (genetic) , lymphoblastic leukemia , medicine , immunology , leukemia , cancer research , biology , antibody , genetics , gene

Treatment with rituximab has improved the outcome for patients with non-Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research